In the private placement, KALA has agreed to sell 1,340,603 shares of its common stock at a price of $6.44 per share and 3,286 shares of its Series I Preferred Stock at a price of $644.00 per share.

ACCORD-2 Phase 3 trial in Alzheimer’s disease agitation achieves primary endpoint compared to placebo (p=0.001, time to relapse)ACCORD-2 Phase 3 ...

The collaborative nature of clinical research creates opportunities for lasting impact. Trial participants play essential ...

Clinical Cancer Research publishes articles that focus on innovative clinical and translational research bridging the laboratory and the clinic. Topics include targeted therapies; mechanisms of drug ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...

Due to their rarity, very few patients with cytotoxic T cell lymphomas are included in clinical trials, meaning very little data exists regarding the efficacy of known T cell lymphoma therapies ...

Preclinical research involves the evaluation of potential therapeutic interventions in cells and animals. Candidates for entry into clinical trials can then be selected based on their ...

Tiziana Life Sciences is expanding its Phase 2 clinical trial testing foralumab nasal spray for the treatment of nonactive secondary progressive multiple sclerosis (SPMS), with six additional ...

Zepbound is currently in Phase 3b of clinical trials meaning that It's a head-to-head study comparing the efficacy and safety of tirzepatide (Zepbound) to semaglutide (Wegovy) in adults with obesity ...

Innovative immunotherapy shows promise in early clinical trial for breast cancer. ScienceDaily . Retrieved December 25, 2024 from www.sciencedaily.com / releases / 2024 / 12 / 241205184431.htm ...

While Applied Therapeutics has vowed to reapply or appeal the FDA’s recent rejection of its rare disease candidate govorestat, deeper issues with the New York biotech’s clinical trial conduct ...